Dsg International Pl (DSITY) 2.4800 $DSITY
Brookfield Asset Management Reports Consolidated Net Income of $3.8 Billion and Funds from Operations of $3.4 Billion
Marketwire - Fri Feb 14, 6:56AM CST
Brookfield Asset Management Inc. (NYSE: BAM)(TSX: BAM.A)(EURONEXT: BAMA) -
MRK: 60.62 (-0.43), BAM: 47.28 (+0.25)
KnowRe Officially Launches Its Award Winning Adaptive Curriculum for Mathematics
Marketwire - Wed Feb 05, 6:30AM CST
Education technology company KnowRe (www.knowre.com) is announcing the launch of its innovative adaptive mathematics curriculum today. After months of improving the product from feedback gathered through its 11,000+ beta users, including students and teachers from 34 pilot schools across the United States, the company is unveiling its official classroom-ready product to K-12 schools and districts nationwide.
DIS: 89.53 (-1.03)
NovoEight (Hemophilia A and
- Forecast and Market Analysis to 2022 Research Report
M2 - Tue Feb 04, 2:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/3k466h/novoeight) has announced the addition of the "NovoEight (Hemophilia A and - Forecast and Market Analysis to 2022" report to their offering. The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden. Novo Nordisk's Novoeight is a short-acting recombinant Factor VIII replacement therapy for the treatment and prevention of bleeding episodes in hemophilia A patients. It is designed to provide patients with increased safety, reliability and portability over other marketed hemophilia A therapies, although it is not a long-lasting factor and does not address the unmet need for longer-acting replacement therapies to reduce the frequency of weekly prophylactic infusions. Scope - Overview of Hemophilia A and B, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on NovoEight including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for NovoEight for the top nine countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Argentina and China. Key Topics Covered: Introduction Disease Overview Disease Management Competitive Assessment Opportunity and Unmet Need Pipeline Assessment Novoeight Appendix List of Tables List of Figures For more information visit http://www.researchandmarkets.com/research/3k466h/novoeight About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends.
BAC: 16.14 (-0.21), NVO: 45.83 (+1.05)
Not the Africa We Want [opinion]
All Africa Global Media - Fri Jan 31, 1:00PM CST
PRESIDENT Robert Mugabe and colleagues from across the continent are in Ethiopia for the African summit where this year there is a nascent buzz phrase "Agenda 2063: The Africa We Want".
MS: 33.85 (-1.01)
Brookfield Asset Management Reports Consolidated Net Income of $3.8 Billion and Funds from Operations of $3.4 Billion
Marketwire - Fri Feb 14, 6:56AM CST
Brookfield Asset Management Inc. (NYSE: BAM)(TSX: BAM.A)(EURONEXT: BAMA) -
MRK: 60.62 (-0.43), BAM: 47.28 (+0.25)
KnowRe Officially Launches Its Award Winning Adaptive Curriculum for Mathematics
Marketwire - Wed Feb 05, 6:30AM CST
Education technology company KnowRe (www.knowre.com) is announcing the launch of its innovative adaptive mathematics curriculum today. After months of improving the product from feedback gathered through its 11,000+ beta users, including students and teachers from 34 pilot schools across the United States, the company is unveiling its official classroom-ready product to K-12 schools and districts nationwide.
DIS: 89.53 (-1.03)
NovoEight (Hemophilia A and
- Forecast and Market Analysis to 2022 Research Report M2 - Tue Feb 04, 2:19AM CST
Research and Markets (http://www.researchandmarkets.com/research/3k466h/novoeight) has announced the addition of the "NovoEight (Hemophilia A and
- Forecast and Market Analysis to 2022" report to their offering. The competitive landscape of hemophilia A and B recombinant therapy in the US and 5EU is dominated by the use of recombinant FVIII and FIX replacement factors, and patients with severe forms of the disease receive frequent prophylactic infusions beginning from the first one or two years of life and often continuing through adulthood. However, the burden on patients and their families to maintain the prophylactic treatment schedule is high, and there is a significant unmet need for new therapies that can reduce the number of weekly prophylactic infusions and alleviate some of this treatment burden. Novo Nordisk's Novoeight is a short-acting recombinant Factor VIII replacement therapy for the treatment and prevention of bleeding episodes in hemophilia A patients. It is designed to provide patients with increased safety, reliability and portability over other marketed hemophilia A therapies, although it is not a long-lasting factor and does not address the unmet need for longer-acting replacement therapies to reduce the frequency of weekly prophylactic infusions. Scope - Overview of Hemophilia A and B, including epidemiology, etiology, symptoms, diagnosis, pathology and treatment guidelines as well as an overview on the competitive landscape. - Detailed information on NovoEight including product description, safety and efficacy profiles as well as a SWOT analysis. - Sales forecast for NovoEight for the top nine countries from 2012 to 2022. - Sales information covered for the US, France, Germany, Italy, Spain, the UK, Japan, Argentina and China. Key Topics Covered: Introduction Disease Overview Disease Management Competitive Assessment Opportunity and Unmet Need Pipeline Assessment Novoeight Appendix List of Tables List of Figures For more information visit http://www.researchandmarkets.com/research/3k466h/novoeight About Research and Markets Research and Markets is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. BAC: 16.14 (-0.21), NVO: 45.83 (+1.05)
Not the Africa We Want [opinion]
All Africa Global Media - Fri Jan 31, 1:00PM CST
PRESIDENT Robert Mugabe and colleagues from across the continent are in Ethiopia for the African summit where this year there is a nascent buzz phrase "Agenda 2063: The Africa We Want".
MS: 33.85 (-1.01)
